Related to Investigators Confirm Role of 12-LO in Beta-Cell Death Associated with Type 1 Diabetes

• Tolerx and GSK Suspend Second Phase III Diabetes Trial as Defend-1 Otelixizumab Study Fails
  
• Otsuka Buys Significant Stake in Living Cell Technologies with $3M
  
• Amylin Allies with JDRF to Evaluate Co-Formulation of Symlin with Insulin
  
• Biodel to Obtain $30M from Registered Direct Offering
  
• Oxford Medical Diagnostics Obtains $1.61M Financing
  
• JDRF to Support Selecta’s Development of Tolerogenic Type 1 Diabetes Vaccine
  
• Diamyd Discontinues U.S. Phase III Trial with Type 1 Diabetes Product
  
• Promising Data for Type 1 and 2 Diabetes Candidates Presented at ADA Meeting
  
• PCT Inks Manufacturing and Service Deal with Islet for Diabetes Transplantation Therapy
  
• Daiichi Sankyo, NGM Partner on Beta-Cell Regenerating Diabetes Therapeutics
  
• DiaKine Awarded $2.1M in Grants from NIH, Iacocca Foundation for Diabetes Therapy
  
• FDA Clears Novo Nordisk’s Levemir for Diabetic Children Aged Two Years and Over
  
• JDRF, BD Expand Diabetes Collaboration to Develop Continuous Glucose Monitoring System
  
• JDRF, Novo Nordisk Ink Type 1 Diabetes Partnership as Firm Opens Seattle R&D Center
  
• Understanding Genetic Risk for Diabetes
  
• Single Gene Mutation May Cause Type 1 Diabetes
  
• Too Much HDL May Be Harmful to Women with Type 1 Diabetes
  
• New Loci Linked with Type 1 Diabetes Identified through Meta-Analysis of GWAS
  
• Researchers Find Approach to Hold Type 1 Diabetes Back
  
• Engineered Gut Bacteria Reverse Type 1 Diabetes in Experimental Mice